Market Research Report
Immunotherapeutic Drugs, Devices & Patient Enablement
|Published by||Greystone Research Associates||Product code||729889|
Delivery time: 1-2 business days
|Immunotherapeutic Drugs, Devices & Patient Enablement|
|Published: October 22, 2018||Content info:||
The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.